相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
Juhani Knuuti et al.
EUROPEAN HEART JOURNAL (2020)
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial
Thomas Vanassche et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
The COMPASS Trial Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease
Jan Steffel et al.
CIRCULATION (2020)
Rivaroxaban in Peripheral Artery Disease after Revascularization
Marc P. Bonaca et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia
Michael S. Conte et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2019)
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
Sonia S. Anand et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry
Arthur Darmon et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
Victor Aboyans et al.
EUROPEAN HEART JOURNAL (2018)
Antithrombotic Therapy in Peripheral Artery Disease
W. Schuyler Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Stuart J. Connolly et al.
LANCET (2018)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Sonia S. Anand et al.
LANCET (2018)
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
W. Schuyler Jones et al.
CIRCULATION (2017)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Marie D. Gerhard-Herman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
Jackie Bosch et al.
CANADIAN JOURNAL OF CARDIOLOGY (2017)
Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50)
Marc P. Bonaca et al.
CIRCULATION (2016)
Epidemiology of Peripheral Artery Disease
Michael H. Criqui et al.
CIRCULATION RESEARCH (2015)
Adherence to Guideline-Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease
Ehrin J. Armstrong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis
F. Gerald R. Fowkes et al.
LANCET (2013)
Bayesian models for subgroup analysis in clinical trials
Hayley E. Jones et al.
CLINICAL TRIALS (2011)
The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Daniel E. Singer et al.
ANNALS OF INTERNAL MEDICINE (2009)
Long-term prognosis of patients with peripheral arterial disease - A comparison in patients with coronary artery disease
Gijs M. J. M. Welten et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
分享论文
